Bronchiolitis in infants is the leading cause of paediatric hospitalisation in Australia accounting for approximately 8000 admissions annually, of which approximately 500-600 are admitted to a paediatric intensive care unit (PICU) requiring respiratory support. None of the current treatments have successfully changed the outcome of the disease or the burden on health care systems. High flow nasal cannula (HFNC) therapy has been used over the last few years in paediatrics with reports showing a reduction in the need for non-invasive and invasive respiratory support. HFNC reduces the work of breathing, improves the gas exchange and can be applied very early…
Principal Investigator:
Dr Christa Bell
Amount Awarded: $69,924
Institution: Gold Coast Hospital and Health Service
